Estimated Long-Term Survival With Eplerenone

Autor:	Faiez Zannad, João Pedro Ferreira, Susan Stienen, John Vincent, Benjamin Li, Nicolas Girerd, Patrick Rossignol, Martijn Busselen, Bertram Pitt, John J.V. McMurray
Přispěvatelé:	Graduate School, Amsterdam Cardiovascular Sciences
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	Male medicine.medical_specialty medicine.drug_class Myocardial Infarction Kaplan-Meier Estimate 030204 cardiovascular system & hematology Health Services Misuse Time Ventricular Dysfunction Left 03 medical and health sciences 0302 clinical medicine Internal medicine Long term survival Humans Medicine cardiovascular diseases 030212 general & internal medicine Myocardial infarction Mineralocorticoid Receptor Antagonists Randomized Controlled Trials as Topic Heart Failure Ejection fraction business.industry Stroke Volume Middle Aged medicine.disease Eplerenone Mineralocorticoid Heart failure Cardiology Female Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of the American College of Cardiology, 73(18), 2357-2359. Elsevier USA
ISSN:	0735-1097
Popis:	Despite Class I recommendations in current American College of Cardiology/American Heart Association guidelines for heart failure (HF) with reduced ejection fraction (HFrEF) and acute myocardial infarction (AMI) with left ventricular systolic dysfunction (LVSD) and/or HF [(1)][1], mineralocorticoid
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eed1bd8323f4f2b96b77eefaa6cb2d5d https://pure.amc.nl/en/publications/estimated-longterm-survival-with-eplerenone(af1eb178-f40a-4f32-bbff-58155c3679c7).html Zobrazit plný text záznamu